trial

A Study for Patients With Schizophrenia

NCTId NCT00520923
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 654 (actual)
Sponsored by Eli Lilly and Company
Primary completion 2008-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
654 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2007-09
Primary completion
2008-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PomaglumetadOlanzapine

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

35 total
Banfield, ArgentinaBuenos Aires, ArgentinaLanús Este, ArgentinaMunro, ArgentinaGraz, AustriaVienna, AustriaOsijek, CroatiaSplit, CroatiaZagreb, CroatiaAachen, GermanyBochum, GermanyDresden, Germany

Linked catalysts

1
A Study for Patients With Schizophrenia — primary completion2008-10

Facts & assertions

4 sourced
Enrollment
654
Phase
PHASE2
Primary Completion Date
2008-10
Status
COMPLETED
relationships
The graph out of here
drug
Pomaglumetad
drug
Olanzapine
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person